Efficacy and tolerability of a pasteurised human fibrinogen concentrate in patients with congenital fibrinogen deficiency

被引:105
作者
Kreuz, W
Meili, E
Peter-Salonen, K
Haertel, S
Devay, J
Krzensk, U
Egbring, R
机构
[1] Aventis Behring GmbH, Dept Clin Res & Dev, D-35002 Marburg, Germany
[2] Univ Frankfurt, Dept Paediat, D-6000 Frankfurt, Germany
[3] Univ Zurich Hosp, Coagulat Lab, Ctr Clin, CH-8091 Zurich, Switzerland
[4] Univ Hosp Bern, Cent Haematol Lab, CH-3010 Bern, Switzerland
[5] Aventis Behring Pharm AG, Zurich, Switzerland
[6] Aventis Behring GmbH, Dept Biometr, Marburg, Germany
[7] Univ Marburg, Dept Internal Med, D-3550 Marburg, Germany
关键词
fibrinogen-deficiency disorders; afibrinogenaemia; fibrinogen substitution; bleedings; coagulation;
D O I
10.1016/j.transci.2004.08.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The efficacy and tolerability of a pasteurised human fibrinogen concentrate were assessed in an open, multi-centre, non-controlled retrospective study in patients with congenital fibrinogen deficiency. Haemostatic efficacy was assessed by laboratory investigation and clinical observation. The study included 12 patients (afibrinogenaemia, n = 8; hypofibrinogenaemia, n = 3; dysfibrinogenaemia combined with hypofibrinogenaemia, n = 1). Fibrinogen substitution was indicated: to stop an ongoing bleed; as prophylaxis before surgery; or for routine prophylaxis to prevent spontaneous bleeding. In total, 151 fibrinogen infusions were recorded. The median single dosage was 63.5 mg/kg body weight for bleeding events or surgery and 76.9 mg/kg for prophylaxis. The median total dose per event for bleeding events or surgery was 105.6 mg/kg. Fibrinogen was administered in 26 bleeding episodes; 11 surgical operations; and 89 prophylactic infusions, of which 86 were received by one patient. The median response (n = 8) was 1.5 mg/dl per substituted mg of fibrinogen per kg body weight (0.8-2.3). The median in vivo recovery (n = 8) was 59.8% (32.5-93.9). Clinical efficacy was very good in all events with the exception of one surgical procedure, where it was moderate. No intercurrent bleeding occurred during prophylaxis. All but one infusion was well tolerated; the patient, who was administered 86 prophylactic infusions, experienced an anaphylactic reaction after the 56th infusion. In addition, one patient developed deep vein thrombosis and non-fatal pulmonary embolism with treatment for osteosynthesis after collum femoris fracture. Fibrinogen substitution could not be excluded as a contributing factor in this high-risk patient. Substitution with pasteurised human fibrinogen concentrate in patients with congenital fibrinogen deficiencies is efficient and generally well tolerated. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:247 / 253
页数:7
相关论文
共 29 条
[1]   CONGENITAL AFIBRINOGENEMIA [J].
ALMONDHIRY, H ;
EHMANN, WC .
AMERICAN JOURNAL OF HEMATOLOGY, 1994, 46 (04) :343-347
[2]  
BECK EA, 1979, CLIN HAEMATOL, V8, P169
[3]  
BINNIE CG, 1993, BLOOD, V81, P3186
[4]   2-STEP FIBRINOGEN-FIBRIN TRANSITION IN BLOOD-COAGULATION [J].
BLOMBACK, B ;
HESSEL, B ;
HOGG, D ;
THERKILDSEN, L .
NATURE, 1978, 275 (5680) :501-505
[5]   Fibrinogen and fibrin-proteins with complex roles in hemostasis and thrombosis [J].
Blomback, B .
THROMBOSIS RESEARCH, 1996, 83 (01) :1-75
[6]  
Brennan SO, 2001, ANN NY ACAD SCI, V936, P91
[7]   SOME PHYSICOCHEMICAL PROPERTIES OF HUMAN FIBRINOGEN [J].
CASPARY, EA ;
KEKWICK, RA .
BIOCHEMICAL JOURNAL, 1957, 67 :41-48
[8]  
DANG CV, 1989, AM J MED, V87, P567
[9]   CORRELATION OF MODE OF FIBRIN POLYMERIZATION WITH PATTERN OF CROSSLINKING [J].
DOOLITTLE, RF ;
CASSMAN, KG ;
CHEN, R ;
SHARP, JJ ;
WOODING, GL .
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1972, 202 (DEC8) :114-126
[10]   Missense mutations in the human β fibrinogen gene cause congenital afibrinogenemia by impairing fibrinogen secretion [J].
Duga, S ;
Asselta, R ;
Santagostino, E ;
Zeinali, S ;
Simonic, T ;
Malcovati, M ;
Mannucci, PM ;
Tenchini, ML .
BLOOD, 2000, 95 (04) :1336-1341